Re: Bonini et al.: Phase 2 randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis (Ophthalmology. 2018;125:1332-1343).

Darren Shu Jeng Ting

Registry-linked trialOpen access · bronzeAbstract readLetterComment

In one paragraph

Article in Ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04627571 (Structural and Functional Changes of Corneal Innervation After Treatment With Cenegermin), which is not on this map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

0.7field-weighted citation impact, top 27% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04627571 completednot on this mapstarted 2022, after this paper: background citation

Structural and Functional Changes of Corneal Innervation After Treatment With Cenegermin

TypeobservationalSponsorUniversity of California, Los AngelesRan2022 to 2025Enrolled8ConditionsNeurotrophic KeratitisArmsCenegermin Ophthalmic Solution [Oxervate]

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

Minimally invasive corneal neurotization for neurotrophic keratopathy: The potential effect of age, denervation chronicity and lesion location.American journal of ophthalmology case reports · 2023
Article
Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy.Orphanet journal of rare diseases · 2022
Observational
A corneal ring ulcer.American journal of ophthalmology case reports · 2020
Article

4 · The record

Corrections and comments

Commented on by
Reply.2019
Comment on
Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.2018

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Darren Shu Jeng TingAcademic Ophthalmology, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, UK. Electronic address: ting.darren@gmail.com.

University of Nottingham · GB

Funding

Medical Research Council MR/T001674/1

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

KeratitisTrigeminal Nerve DiseasesDouble-Blind MethodHumansNerve Growth FactorNerve Growth Factor

Identifiers

PMID30683186

DOI10.1016/j.ophtha.2018.09.017

OpenAlexW2913673505

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

NCT04627571ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.